"Our mandate is to become No. 1 in everything we enter into, so our long-term goal is to become a leading pharmaceutical company in the world."
That's what Christopher Hansung Ko, CEO of Samsung's (NASDAQOTH: SSNLF ) Bioepis unit, had to say about his company's unexpected dive into biotech.
Of course, to become that dominant, Samsung would have to beat a lot of other pharma companies -- and face off against Google (NASDAQ: GOOGL ) (NASDAQ: GOOG ) , whose investments in Calico to combat aging also have transformative possibilities.
The Korean conglomerate is looking to compete in biosimilars, or the generic versions of biologic drugs, and it's paired up with a number of health care heavyweights (including Biogen) to make that happen. It's a pretty target-rich environment, and a market that may be worth as much as $24 billion by 2019. Samsung isn't idly grabbing headlines either -- it's investing $2 billion to get this foray started, with the expectation of selling $1.8 billion a year in biopharmaceutical products by 2020.
In the following video, from Market Checkup, the Motley Fool's health care-focused investing show, Motley Fool health care analysts Michael Douglass and David Williamson dig into the details and look at the investing takeaways in this surprising and exciting story.
Can Google and Samsung keep up with this incredible stock?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.